BIOMAT Database Logo BIOMAT Database Logo

Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options. 2013

Steven L Flamm
Professor of Medicine-Gastroenterology and Hepatology and Surgery Northwestern University Feinberg School of Medicine Chicago, Illinois.

UI MeSH Term Description Entries

Related Publications

Steven L Flamm
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
May 2013, The New England journal of medicine,
Steven L Flamm
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
November 2015, Gastroenterology,
Steven L Flamm
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
May 2015, Annals of internal medicine,
Steven L Flamm
Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.
January 2016, Expert review of gastroenterology & hepatology,
Steven L Flamm
Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
May 2017, Journal of viral hepatitis,
Steven L Flamm
Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
September 2018, Liver international : official journal of the International Association for the Study of the Liver,
Steven L Flamm
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.
January 2020, Hepatology (Baltimore, Md.),
Steven L Flamm
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.
October 2017, Hepatology (Baltimore, Md.),
Steven L Flamm
Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection.
January 2006, Drugs,
Steven L Flamm
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
May 2017, Gastroenterology,
Copied contents to your clipboard!